Literature DB >> 24836079

Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: a Danish nationwide, population-based cohort study.

Lise M Lindahl1, Morten Fenger-Grøn2, Lars Iversen3.   

Abstract

BACKGROUND: Data on subsequent cancers, prognostic factors for mortality, and causes of death are limited in mycosis fungoides (MF) and parapsoriasis.
OBJECTIVES: To assess subsequent cancers, mortality, and causes of death in MF and parapsoriasis.
METHODS: Using the Danish nationwide population-based registries, we identified 368 MF patients and 582 parapsoriasis patients and compared them with the general Danish population for subsequent cancers, mortality, and causes of death.
RESULTS: Subsequent cancers were significantly increased in parapsoriasis patients (standardized incidence ratio [SIR], 2.0 [95% confidence interval {CI}, 1.6-2.5]), and a trend was observed in MF (SIR, 1.2 [95% CI, 0.9-1.5]). Mortality was significantly increased in MF (SIR, 2.0 [95% CI, 1.8-2.3]) and parapsoriasis (SIR, 1.3 [95% CI, 1.1-1.5]). Excess mortality from MF was highest during the first 5 years of follow-up, and causes of increased death included both malignant and nonmalignant diseases. LIMITATIONS: We have no information regarding clinical stage, treatments, and patient lifestyles.
CONCLUSION: Patients with parapsoriasis had a significantly increased risk of subsequent cancers and increased mortality. In addition, the highest excess mortality in the MF group was observed during the first 5 years of follow-up, which suggests that MF exists in both an aggressive and a more indolent form.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  causes of death; cutaneous T-cell lymphoma; mortality; mycosis fungoides; parapsoriasis; subsequent cancers

Mesh:

Year:  2014        PMID: 24836079     DOI: 10.1016/j.jaad.2014.03.044

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis.

Authors:  Amrita Goyal; Daniel O'Leary; Kavita Goyal; Nathan Rubin; Kimberly Bohjanen; Maria Hordinsky; Steven T Chen; Georgios Pongas; Lyn M Duncan; Aleksandr Lazaryan
Journal:  J Am Acad Dermatol       Date:  2019-07-30       Impact factor: 11.527

2.  Investigating heredity in cutaneous T-cell lymphoma in a unique cohort of Danish twins.

Authors:  N Odum; L M Lindahl; M Wod; T Krejsgaard; A Skytthe; A Woetmann; L Iversen; K Christensen
Journal:  Blood Cancer J       Date:  2017-01-20       Impact factor: 11.037

3.  Exacerbation of mycosis fungoides leading to the diagnosis of chronic myelomonocytic leukemia.

Authors:  Rose K C Moritz; Dieter Metze; Stefanie Wiebe; Andrea Kerkhoff; Wolfgang E Berdel; Carsten Weishaupt
Journal:  JAAD Case Rep       Date:  2018-03-06

Review 4.  Parapsoriasis-A Diagnosis with an Identity Crisis: A Narrative Review.

Authors:  Manasmon Chairatchaneeboon; Kanchalit Thanomkitti; Ellen J Kim
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-15

5.  Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population.

Authors:  Shany Sherman; Noa Kremer; Adam Dalal; Efrat Solomon-Cohen; Einav Berkovich; Yehonatan Noyman; Maya Ben-Lassan; Assi Levi; Lev Pavlovsky; Hadas Prag Naveh; Emmilia Hodak; Iris Amitay-Laish
Journal:  Acta Derm Venereol       Date:  2020-12-09       Impact factor: 3.875

6.  Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center.

Authors:  Subuhi Kaul; Micah Belzberg; John-Douglas Matthew Hughes; Varun Mahadevan; Raveena Khanna; Pegah R Bakhshi; Michael S Hong; Kyle A Williams; Annie L Grossberg; Shawn G Kwatra; Ronald J Sweren
Journal:  Medicines (Basel)       Date:  2019-12-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.